DxUpClose Raises $1.0M

Dallas-based DxUpClose, whic is developing in-vitro, antibiotic sensitivity tests, has raised $1.0M in a Series A funding. The round came from angel investment group Golden Seeds. According to Golden Seeds, which announced the funding this morning, the technology being developed by DxUpCLose is initially being targeted at urinary tract infections, allowing physicians to determine, in real time what the best antibiotics to prescribe are for an issue. DxUpClose is based on research from both Texas A&M University and Texas State University. The firm was founded by Cyndi Nickel, a former HP executive, in 2009. Golden Seeds is an angel investment group which focuses on investing in women entrepreneurs. More information »